I don't remember seeing this letter before, but I spent a lot of time reading through it today. I know it is almost 2 years old and the FDA ignored a lot of the comments sent in response to the (proposed, at that time) deeming, but still, my shorts became twisted reading it.
They apparently feel they are above the rules set in place for them, how did they even pull this off? I wonder if they changed anything before it went to OMB, or if the OMB even LOOKED at the thing before they said, um, ok?
From page 24:
Since the enactment of the proposed rule would have a substantial impact on business, consumers and the economy, it is what the Office of Management and Budget defines as a “significant” regulation. This means that the
FDA is required to perform a regulatory impact analysis (RIA) under the guidelines set out under Executive Order 12866, Executive Order 13563, the Regulatory Flexibility Act (5 U.S.C. 601-612), and the Unfunded Mandates Reform Act of 1995 (Public Law 104-4).
Under these provisions the
FDA must not only determine if the regulation is necessary but must assess all costs and benefits of available regulatory alternatives to select approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). It also
requires the FDA to among other things analyze regulatory options that would minimize any significant impact of a rule on small entities.
From pages 27 and 28:
"According to the Office of Management and Budget, there are
16 key elements that every Regulatory Impact Analysis needs to address.......In addition to these 16 items, a proper RIA must examine a number of additional impacts including international effects and the effects on small businesses."
"Simply put, the RIA performed by the FDA staff for the proposed rule is significantly lacking in respect to the provisions outlined by the OMB. .......the analysis of the effect on small businesses was so inadequate as to encourage the Small Business Administration to offer its assistance to the FDA in completely redrafting the RIA. Looking just at the provisions outlined by the OMB,
the RIA fails to perform 14 of the 16 checklist items."
I don't know why these particular details struck me harder than the rest of them, but I'm glad to know that SFATA has these experts working with/for them. Sorry for the long post, thanks for listening. I have been following the thread since day one and will continue to follow, but this makes me so angry!
I